Market Research Report
Asia Pacific Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; End User
|Asia Pacific Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product ; End User|
Published: May 6, 2021
The Insight Partners
Content info: 149 Pages
Delivery time: 1-2 business days
The anticoagulant reversal drug market in Asia Pacific is expected to grow from US$ 173.5 million in 2019 to US$ 444.8 million by 2027; it is estimated to grow at a CAGR of 13.2% from 2019 to 2027. Anticoagulant reversal drugs are used in the management of hemorrhagic stroke to decrease bleeding and allow tissues to recover. There has been increase in stroke prevalence in low- and middle-income countries. As per the study "Incidence & prevalence of stroke in India: A Systematic Review," published in 2017, the cumulative frequency of stroke in India ranged from 105 to 152 per 100,000 persons per year. These values are higher than those in high-income countries. Such high prevalence of stroke contributes to the high demand for anticoagulant reversal drugs in Asia Pacific countries.
Based on product, the Asia Pacific anticoagulant reversal drugs market is segmented into prothrombin complex concentrates, vitamin K, AndeXXa, protamine, idarucizumab, and tranexamic acid. In 2019, the vitamin K segment accounted for the largest market share. It is a reliable and fast alternative to fresh frozen plasma to control excessive bleeding as it has properties to reverse the effects of oral anticoagulant treatments, which contributes to the wide acceptance for this product. On the other hand, the market for AndeXXa is expected to grow at the fastest CAGR during the forecast period.
The Covid-19 outbreak in late January 2020 has led to an overwhelming demand for anticoagulant reversal drugs due to the rising demand for hospital beds. China and India are among the key contributors to the global drug discovery and manufacturing. Healthcare professionals are innovating and developing procedures to treat heart failure in COVID-19 infected patients. For instance, in October 2020, the experts in the University of Sydney discovered a method to treat highly contagious COVID-19 patients with ailing hearts within intensive care units. This is expected to be the pioneer study that has been fast-tracked for COVID-19 patients with cardiovascular complexities. Further, it is assumed to be useful for treating acute heart failure, in general. Thus, the anticoagulant reversal drug market in the Asia Pacific has witnessed minimal impact of the pandemic.
The Asia Pacific anticoagulant reversal drug market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining overview and forecast for the Asia Pacific anticoagulant reversal drug market with respect to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants of this process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers-along with external consultants such as valuation experts, research analysts, and key opinion leaders-specializing in the Asia Pacific anticoagulant reversal drug market. Boehringer Ingelheim International GmbH, Pfizer Inc, Octapharma AG, Fresenius Kabi AG, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), CSL Limited, and Grifols, S.A., China Biologic Products, Inc., and Shanghai RAAS Blood Products Co., Ltd. are among the players operating in the market in this region.
Source: The Insight Partners Analysis, Website, Press Releases and Others